Thankyou @kombikarlos this really helps . Would the fees charged...

First 6 Last

Share
Profile

Follow
Plext

10,623 Posts.

1261

31/05/17

09:44

Post #: 25007808
Share

Originally posted by kombikarlos ↑

OK Plext, I'll do my best !

(All, please note I only venture on here to deal with "facts" not to express an opinion about sentiments expressed, etc....otherwise a man could be on here all day!)

I'll start by saying that there will only be a potential CGT liability at the time of an actual disposal of the shares. Moving SOLG from AIM to LSE, and dual-listing SOLG on TSX will not trigger a "disposal" in itself, so no problem there.

So, onto Einstein's General Theory of Capital Gains Tax.....

Essentially, where DGR disposes of any listed shares that it holds, it would pay 30% corporate tax on the “profit” made on the sale (proceeds less cost of investment). Admittedly, for companies like SOLG and IRR, the cost base of the shares is substantially below their value and any disposal would result in a profit / capital gain being realized.

Again from a general perspective, income or capital gains tax paid by a company gives rise to “franking credits” which are passed on to shareholders as a tax credit when the company pays a dividend. This is a system to essentially avoid double-taxation of the same underlying profit (once in the hands of the company and again in the hands of the shareholder). So whilst the initial payment of the tax by the company is a "negative" (ie. cash out the door) it's more or less parked in a "bank" and will ultimately be of benefit to shareholders when cash and / or income provide the company with the ability to pay dividends through to shareholders.

In my view the latent tax liability is part of (but not the whole) reason as to why DGR is discounted heavily against the NTA backing.

K

Expand

Thankyou @kombikarlos this really helps . Would the fees charged by the directors increase the cost base thus lowering the amount of tax ?

DGR Price at posting: 13.0¢ Sentiment: None Disclosure: Held
Upvote

0 Great analysis

Reply

Top Stories

RCE

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

COB

Cobalt Blue sees A$60M price tag for Kwinana, WA refinery – but $68M value for stage one

OJC

SPC to merge with Original Juice Co and Nature One Dairy

COD

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

ACW

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

There are more pages in this discussion • 1 more message in this thread...

First 6 Last

Add DGR (ASX) to my watchlist

(20min delay)
Last 1.4¢		Change -0.002(12.5%)		Mkt cap ! $14.61M

Open	High	Low	Value	Volume
1.6¢	1.6¢	1.4¢	$16.05K	1.065M

Buyers (Bids)

No.	Vol.	Price($)
2	830000	1.3¢

Sellers (Offers)

Price($)	Vol.	No.
1.6¢	540000	1

View Market Depth

No.	Vol.	Price($)
2	830000	0.013
2	583333	0.012
2	363636	0.011
3	450099	0.010
0	0	0.000

Price($)	Vol.	No.
0.016	540000	1
0.018	550000	1
0.019	1090240	2
0.020	1532270	2
0.025	32000	1

Last trade - 15.36pm 02/10/2024 (20 minute delay)

DGR (ASX) Chart

Thankyou @kombikarlos this really helps . Would the fees charged...

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

Cobalt Blue sees A$60M price tag for Kwinana, WA refinery – but $68M value for stage one

SPC to merge with Original Juice Co and Nature One Dairy

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

Thankyou @kombikarlos this really helps . Would the fees charged...

Top Stories

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

Cobalt Blue sees A$60M price tag for Kwinana, WA refinery – but $68M value for stage one

SPC to merge with Original Juice Co and Nature One Dairy

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News